Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,828 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Among authors: patel v. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis.
Vergis N, Patel V, Bogdanowicz K, Czyzewska-Khan J, Fiorentino F, Day E, Cross M, Foster N, Lord E, Goldin R, Forrest E, Thursz M. Vergis N, et al. Among authors: patel v. Trials. 2021 Nov 11;22(1):792. doi: 10.1186/s13063-021-05719-2. Trials. 2021. PMID: 34763711 Free PMC article.
Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study Group.
Sussman G, Shurman J, Creed MR, Larsen LS, Ferrer-Brechner T, Noll D, Allegra J, Montgomery R, Schreck D, Grafstein E, Ramalanjaona G, Patel V, Ducharme J, Ortenwall P, Foster E, Ames M. Sussman G, et al. Among authors: patel v. Clin Ther. 1999 Jul;21(7):1216-27. doi: 10.1016/s0149-2918(00)80024-7. Clin Ther. 1999. PMID: 10463519 Clinical Trial.
Utility of scores to predict alcohol use after liver transplant (lt): take them with a grain of salt.
Houston K, Duong N, Sterling RK, Asgharpour A, Bullock S, Weinland S, Keller N, Smirnova E, Khan H, Matherly S, Wedd J, Lee H, Siddiqui M, Patel V, Arias A, Kumaran V, Lee S, Sharma A, Khan A, Imai D, Levy M, Bruno D. Houston K, et al. Among authors: patel v. Liver Transpl. 2024 May 23. doi: 10.1097/LVT.0000000000000407. Online ahead of print. Liver Transpl. 2024. PMID: 38775570
Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
Coutts SB, Ankolekar S, Appireddy R, Arenillas JF, Assis Z, Bailey P, Barber PA, Bazan R, Buck BH, Butcher KS, Camden MC, Campbell B, Casaubon LK, Catanese L, Chatterjee K, Choi PMC, Clarke B, Dowlatshahi D, Ferrari J, Field TS, Ganesh A, Ghia D, Goyal M, Greisenegger S, Halse O, Horn M, Hunter G, Imoukhuede O, Kelly PJ, Kennedy J, Kenney C, Kleinig TJ, Krishnan K, Lima F, Mandzia JL, Marko M, Martins SO, Medvedev G, Menon BK, Mishra SM, Molina C, Moussaddy A, Muir KW, Parsons MW, Penn AMW, Pille A, Pontes-Neto OM, Roffe C, Serena J, Simister R, Singh N, Spratt N, Strbian D, Tham CH, Wiggam MI, Williams DJ, Willmot MR, Wu T, Yu AYX, Zachariah G, Zafar A, Zerna C, Hill MD; TEMPO-2 investigators. Coutts SB, et al. Lancet. 2024 May 16:S0140-6736(24)00921-8. doi: 10.1016/S0140-6736(24)00921-8. Online ahead of print. Lancet. 2024. PMID: 38768626
5,828 results